Tradestie Institutional Equity Comparison Engine
REPL vs CRMD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRMD Overall Edge
CRMD Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while REPL counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, REPL trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CRMD at 29.5x Forward P/E and 41.0% operating margin (-47.7% YoY). In options structure, REPL sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro) against CRMD sits in BREAKDOWN (90th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CRMD
REPL N/M vs CRMD 29.5x Fwd P/E
Growth & Margin Winner
CRMD
Op Margin 0.0% vs 41.0% ยท YoY +0.0% vs -47.7%
Momentum & Technical Winner
REPL
1Y +119.3% vs -58.5% ยท 52W Pos 82% vs 0%
Options & Structure Winner
REPL
BREAKOUT (23rd %ile IV) vs BREAKDOWN (90th %ile IV)
REPL
NASDAQ
Replimune Group, Inc.
Biological Products, (No Disgnostic Substances)
$19.69
-8.03% 1D
Market Cap
$2.1B
1M Return
+78.19%
1Y Return
+119.27%
Forward P/E
N/M
Unified AI Score
34.8 / 100
SELL
Tech 16.0
Fund 44.0
Flow 70.0
Mom 60.0
CRMD
NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.67
-3.11% 1D
Market Cap
$370.6M
1M Return
-36.72%
1Y Return
-58.45%
Forward P/E
29.5x
Unified AI Score
55.5 / 100
HOLD
Tech 60.0
Fund 62.0
Flow 70.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
REPL +119.27%
CRMD -58.45%
Spread: +177.47 pp (REPL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
REPL TTM Op. Margin: 0.0%
CRMD TTM Op. Margin: 41.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REPL vs CRMD. Trailing 12-month operating profitability (REPL 0.0% vs CRMD 41.0%) and valuation multiples (REPL N/M vs CRMD 29.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | REPL | CRMD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $370.6M | Larger Scale | REPL |
| Trailing P/E Ratio Valuation | N/M | 2.4x | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | N/M | 29.5x | Lower Multiple | CRMD |
| Revenue Growth (YoY) Growth | +0.0% | -47.7% | Higher Growth | REPL |
| Operating Margin (TTM) Profitability | 0.0% | 41.0% | Higher Margin | CRMD |
| Net Profit Margin Profitability | 0.0% | 15.5% | Higher Margin | CRMD |
| Return on Equity (ROE) Capital Efficiency | -115.8% | 15.3% | Higher ROE | CRMD |
| 52-Week Range Position Momentum | 82% ($2โ$24) | 0% ($5โ$13) | Stronger Trend | REPL |
| Beta / 30D Volatility Risk Regime | 2.15ฮฒ ยท 105% Vol | 1.22ฮฒ ยท 103% Vol | Lower Realized Risk | CRMD |
| Unified Institutional Score Composite Signal | 34.8 / 100 (SELL) | 55.5 / 100 (HOLD) | Higher Composite | CRMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full REPL vs CRMD Buy Guide
REPL
BREAKOUT
99d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
CRMD
BREAKDOWN
110d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
90th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither REPL nor CRMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.